Cardiovascular Diagnostic Testing Market Outlook
Cardiovascular Diagnostic Testing Market size was over USD 12.8 billion in 2024 and is estimated to reach USD 29.2 billion by the end of 2037, expanding at a CAGR of 7.1% during the forecast timeline, i.e., 2025-2037. In 2025, the industry size of the cardiovascular diagnostic testing is estimated at USD 13.7 billion.
The rising cases of heart-related diseases are becoming a global concern, which is creating a surge for early detection and intervention, hence fueling the market. According to the Centers for Disease Control and Prevention (CDC), in 2024, the U.S. alone consists of 126.4 million adult population afflicted with these ailments. Similarly, from 2018 to 2025, Germany witnessed a 14.3% rise in cardiovascular disease (CVD) events, accounting for 9.3 million in 2025. This demonstrates a sustainable growth in demand for diagnostic solutions available in this field. Moreover, rapid aging among residents from across the world is also propelling the volume of this demography.
Despite worldwide adoption, the economic burden from high payers’ pricing in the market is still persistent. This can be displayed by the inflation in the producer price index (PPI) for medical diagnostic equipment, showcasing a 4.3% year-over-year (YoY) rise, as per the 2024 report from the U.S. Bureau of Labor Statistics, 2024. This is a result of heightened production costs due to semiconductor shortages and supply chain disruptions. Further, the upward trajectory is passed through to a 5.2% annual increase in the consumer price index (CPI) for cardiac testing services, according to the Organisation for Economic Co-operation and Development (OECD).
Cardiovascular Diagnostic Testing Market Growth Drivers and Challenges
Growth Drivers
-
Contribution to reducing healthcare costs and mortality: The propelled pace of expansion in the cardiovascular diagnostic testing market is significantly compelled by the clinical validation of its cost-saving potential. The same is portrayed through a study from the Agency for Healthcare Research and Quality (AHRQ), published in 2022. The trial found that early CVD diagnosis can reduce hospitalizations by 18.3%, generating substantial savings of $4.8 billion over just two years. Such findings underscore the economic value of testing commodities, creating a strong foundation for this sector. The demonstrated return on investment is also driving the adoption of advanced testing solutions across care settings.
-
Investments and engagement in innovation: Future progress in the cardiovascular diagnostic testing market is drafted over the substantial R&D investments from major funding entities. In this regard, in 2024, the National Institute of Health (NIH) allocated $2.5 billion for research on CVD detection methods, with a prime focus on breakthrough technologies, such as AI-powered ECG interpretation and portable imaging solutions. Complementing this effort, in the same year, the Horizon Europe program committed €1.2 billion to cardiovascular diagnostic innovations, including advanced non-invasive testing tools. Such public and private R&D investments are catalyzing integrations and commercialization of next-generation technologies.
Historical Patient Growth (2010-2020): Foundation for Future Market Expansion
The decade passed over the timeline from 2010 to 2020 imposed a transformative phase in the cardiovascular diagnostic testing market worldwide. Rapid aging, greater disease awareness, and the introduction of technologically advanced diagnoses collectively expanded the volume of the patient pool. For instance, developed nations, such as the U.S. and Germany, witnessed accelerated uptake of CVD affliction due to the enlarging obese and hypertensive population. Whereas, in emerging economies, including China and India, infrastructural development in healthcare spurred the number of diagnosed patients. Moreover, the increased per-capita testing rates acted as a testament to a strong and reliable consumer base for this sector.
Historical Patient Growth Data (2010-2020)
|
Country |
2010 Patients (Million) |
2020 Patients (Million) |
Growth (%) |
Key Driver |
|
U.S. |
18.3 |
29.8 |
63.1% |
Medicare expansion, ACA policies |
|
Germany |
6.9 |
9.6 |
40.3% |
DMPs, aging population |
|
France |
5.2 |
7.4 |
43.3% |
National heart health initiatives |
|
Spain |
4.0 |
5.7 |
44.1% |
Telecardiology adoption |
|
Australia |
2.5 |
3.8 |
54.4% |
Govt. CVD screening subsidies |
|
Japan |
12.7 |
17.0 |
34.2% |
Elderly care mandates |
|
India |
8.6 |
19.3 |
126.1% |
Private hospital network expansion |
|
China |
23.5 |
48.2 |
106.2% |
Rural health campaigns |
Feasible Expansion Models Shaping the Future of Cardiovascular Diagnostic Testing
The commercial outputs in the cardiovascular diagnostic testing market are being shaped by distinct regional approaches tailored to local needs and scenarios. For instance, in emerging economies, manufacturers are adopting low-cost production strategies and public-private partnerships (PPPs) to improve rural access. This is further exemplified by a 12.1% revenue boost in India in 2024 through collaborations with clinics. On the other hand, developed landscapes are prioritizing the development of premium-priced, AI-enhanced solutions and alignment with domestic reimbursement frameworks. The same can be seen in Germany, where disease management programs generated €300.4 million in revenue from public sector contracts in 2023.
Revenue Feasibility Models (2020-2024)
|
Model |
Region |
Revenue Impact |
Key Driver |
|
Local Manufacturing |
China |
$1.3 billion cost savings |
NMPA reagent localization mandates |
|
Telehealth Kits |
U.S. |
18.2% higher margins |
CMS reimbursement for remote monitoring |
|
PPPs |
India |
12.1% revenue growth |
Govt. Ayushman Bharat subsidies |
|
AI Licensing |
EU |
€200.1 million/year |
EMA fast-track for AI diagnostics |
Challenges
-
Hurdles in attaining universal compliance: Delays in regulatory approval processes often cause significant financial losses in the cardiovascular diagnostic testing market by slowing innovation and product debut. For instance, in Japan, approval delays have increased substantially, with new CVD diagnostic approvals taking 6.2 months longer in 2023 due to stricter compliance criteria. Similarly, the Breakthrough Device program from the U.S. FDA shows notable bottlenecks, having cleared only 18 out of 45 submitted AI cardiology tools in 2023. These foster barriers for manufacturers and development costs increase. Moreover, the elongated process of clearance is potentially limiting market availability.
-
Inconsistent payer policies across regions: The inconsistent reimbursement coverage across different healthcare systems creates a disparity in the cardiovascular diagnostic testing market. For instance, in Brazil, the public health system (SUS) covered only 30.4% of major cardiac tests till 2024. This is evident even within key landscapes, such as the U.S., where manufacturers are bound to navigate complex state-by-state Medicaid variations. However, by mitigating this issue with targeted waiver approvals, Abbott conducted a successful expansion of access to 1.3 million additional patients in 2024.
Cardiovascular Diagnostic Testing Market Size and Forecast:
| Report Attribute | Details |
|---|---|
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
7.1% |
|
Base Year Market Size (2024) |
USD 12.8 billion |
|
Forecast Year Market Size (2037) |
USD 29.2 billion |
|
Regional Scope |
|
Cardiovascular Diagnostic Testing Market Segmentation
Product Segment Analysis
The cardiac imaging systems segment is poised to capture the largest share of 35.2% in the cardiovascular diagnostic testing market by the end of 2037. The shifting consumer preference toward non-invasive detection tools, such as FFR-CT technologies, is the primary driver behind the segment's proprietorship. In addition, considering the clinically proven efficacy of this equipment, insurers from across the globe are showing interest in expanding their financial backing, inspiring more patients to undergo cardiac imaging. For instance, in 2025, the U.S. Medicare extended coverage for these advanced imaging modalities, as per the Centers for Medicare & Medicaid Services (CMS)
End user Analysis
The hospitals & cardiac centers segment is expected to garner a considerable share of 25.5% in the cardiovascular diagnostic testing market over the assessed period. Having a critical role in the centralized medical system, these facilities are becoming the primary point of care for afflicted patients worldwide. This is amplifying the segment's contribution to the revenue generation in this sector. Additionally, hospitals are the most suitable settings for comprehensive cardiovascular evaluations on account of housing advanced diagnostic equipment and specialized clinical expertise. Moreover, with increasing investments to enhance public access to state-of-the-art cardiac care, this segment is gaining traction.
Our in-depth analysis of the cardiovascular diagnostic testing market includes the following segments:
|
Product |
|
|
End user |
|
Vishnu Nair
Head - Global Business DevelopmentCustomize this report to your requirements — connect with our consultant for personalized insights and options.
Cardiovascular Diagnostic Testing Market Regional Analysis
North America Market Insights
North America is projected to dominate the global cardiovascular diagnostic testing market with a 38.3% revenue share throughout the discussed timeline. The high CVD burden and advanced healthcare infrastructure are collectively establishing the region's significance as a profitable landscape. In this regard, the CDC reported that the number of adults with cardiovascular disease in North America reached 48.2 million in 2024. It also mentioned that the yearly count of new CVD incidences surpassed 12.6 million new cases in the same year.
The U.S. is maintaining its position as the region's largest cardiovascular diagnostic testing market, backed by substantial public spending and insurer policy support. For instance, in 2024, Medicaid invested $1.9 billion in improving rural access to portable ECG devices, while a $2.2 billion fund was allocated for AI-cardiology R&D by the NIH in 2025. These financial backings are accelerating technological development and adoption in this sector. However, headwinds from hospital consolidation have pressured supplier margins by 12.2% in 2024, according to a study from the AHRQ. This is creating both opportunities and challenges for industry participants in this advanced yet competitive landscape.
The Canada cardiovascular diagnostic testing market is projected to grow at a steady pace on account of provincial government healthcare investments. For instance, in 2024, the governing authorities in Ontario allocated $320.3 million to telecardiology, reflecting the country's potential to cultivate tech-based advances in this sector. Further, regulatory updates are also inspiring both domestic and foreign MedTech pioneers to participate in this field of commercial operation. Testifying the same, in 2024 alone, Health Canada approved 15 new AI-driven tests, that have already reduced diagnostic delays by 40,2%. However, uneven reimbursement policies continue to challenge market expansion.
APAC Market Insights
Asia Pacific is expected to register the highest CAGR of 8.3% in the global cardiovascular diagnostic testing market over the analyzed tenure. This propagation is primarily attributable to the healthcare access expansion initiatives for underserved areas. As evidence, the government of Japan subsidized the procurement of AI-based diagnostic solutions for enhanced cardiac care, which propelled adoption in this field by 20.3% in 2024, according to a report from the MHLW. Similarly, in 2024, South Korea escalated the deployment of cardiovascular diagnostic testing (CDT) in hospitals by 30.4%, as per the Ministry of Food and Drug Safety (MFDS)
China leads the APAC cardiovascular diagnostic testing market with continuous capital influx from public investors. $8.2 billion in spending on this category, in 2024, reflecting a 15.4% YoY rise. Further, the National Medical Products Administration (NMPA) aimed to achieve 70.2% local production of IVD reagents by 2030, to strengthen domestic capabilities. Telecardiology adoption also underscored the country's significance, where 1.6 million patients are diagnosed through remote platforms nationwide. This demonstrates the government's commitment to cultivating sufficient resources to expand in this field. These initiatives are positioning domestic manufacturers at the forefront of the regional landscape.
The cardiovascular diagnostic testing market in India is also expanding rapidly, with immense government support. The government's increased investments highlight India's commitment to improving cardiac care access while presenting significant potential for diagnostic manufacturers. Testifying the same, in 2024, the Ayushman Bharat scheme allocated $1.9 billion in funding to cover 2.5 million patients. These conditions create greater opportunities for this country as a price-sensitive landscape, where affordable, scalable diagnostic solutions are urgently needed to bridge the urban-rural healthcare divide.
Country-wise Provisions by Government
|
Country |
Policy/Initiative |
Budget/Funding (Million) |
Launch Year |
Key Impact |
|
Australia |
Medicare Coverage Expansion for Cardiac CT |
AUD 320.3 |
2024 |
Covers 100,000+ patients annually for advanced imaging |
|
Japan |
METI MedTech Fund for AI Diagnostics |
≈$340.4 |
2025 |
Targets 20.1% local production of CDT hardware by 2030. |
|
South Korea |
AI-Based Stress Test Development Program |
$500.2 |
2023 |
Reduced diagnosis time by 40.2% (MFDS). |
|
Malaysia |
Portable Ultrasound Initiative for Rural Care |
MYR 900.3 |
2022 |
Doubled patient coverage since 2021 (MOH). |
Europe Market Insights
The Europe cardiovascular diagnostic testing market is estimated to exhibit steady growth by 2037. The region's augmentation is pledged to demographic aging and AI adoption, where Germany commands a 32.4% revenue share, followed by the UK and France. Government initiatives, such as the €2.6 billion EHDS investment in digital cardiology tools in 2024, complement its successes in tech-based innovations and deployment. This can also be exemplified by a 15.4% reduction in CVD hospitalizations due to the implementation of Disease Management Programs (DMPs) across Germany. However, restrictive reimbursement policies for advanced imaging are still persistent as a complex challenge in wide adoption.
The UK cardiovascular diagnostic testing market is experiencing strong growth, with the NHS dedicating 8.4% of its budget to these technologies in 2024. This allocation further contributed to a 12.1% YoY demand increase and drove access expansion by telecardiology pilots in rural areas. Whereas, nationwide prioritization of AI-ECG technologies, which reduce wait times by 25.1%, also represents the presence of a progressive atmosphere, according to the National Health Service (NHS). The country's focus is now concentrated on digital health innovations and equitable service distribution, positioning it as the region's second-largest marketplace.
Germany is solidifying its position as a regional leader in the cardiovascular diagnostic testing market, attributable to government allocations. For instance, in 2024, the country's governing body invested €4.3 billion, which drove FFR-CT adoption by 30.4%. Further, the incorporation of AI-based troponin tests in the reimbursement overhaul of the Federal Joint Committee (G-BA)by 2025 also enhanced accessibility in this sector. Moreover, the nation's robust healthcare infrastructure and proactive adoption of advanced cardiac diagnostics make it the continent's most advanced marketplace.
Key Cardiovascular Diagnostic Testing Market Players
The cardiovascular diagnostic testing market is dominated by a consortium of MedTech innovators, including Abbott, Roche, Siemens, Medtronic, and GE, which collectively control over 50.4% of the global revenue. These industry leaders are driving innovation through AI integration and rigorous R&D involvement. For instance, Roche and Siemens are consolidating their position in this field with their FDA/CE-approved AI diagnostic solutions that can reduce errors by 30.2%. On the other hand, suppliers in emerging landscapes are localizing production in India and China to escalate adoption rates by reducing costs by 25.3%.
This cohort of key players include:
|
Company Name |
Market Share (2024) |
Industry Focus |
|
Abbott Laboratories |
12.6% |
Leading in cardiac biomarkers (Troponin tests) & portable ECG devices. |
|
Roche Diagnostics |
11.9% |
Dominates high-sensitivity troponin assays & AI-powered lab diagnostics. |
|
Siemens Healthineers |
10.3% |
Advanced imaging (CT/MRI) & AI-based FFR-CT solutions. |
|
Medtronic |
9.6% |
Cardiac monitors, implantable loop recorders, and remote patient monitoring. |
|
GE Healthcare |
8.8% |
Echocardiography systems & AI-integrated cardiac imaging. |
|
Philips Healthcare |
xx% |
Wearable ECG patches & telecardiology platforms. |
|
Becton Dickinson |
xx% |
IVD reagents & point-of-care cardiac testing. |
|
Danaher |
xx% |
Automated lab analyzers for cardiac biomarker testing. |
|
BioMerieux |
xx% |
Infectious disease diagnostics impacting CVD complications. |
|
B. Braun |
xx% |
Vascular access devices & cardiac catheters. |
|
LivaNova |
xx% |
Cardiac surgery equipment & neuromodulation devices. |
|
Mindray Medical |
xx% |
Affordable ECG machines & ultrasound systems. |
|
Trivitron Healthcare |
xx% |
Low-cost cardiac imaging solutions for emerging markets. |
|
OSANG Healthcare |
xx% |
Rapid cardiac biomarker test kits & POC devices. |
|
Edwards Lifesciences |
xx% |
Hemodynamic monitoring systems for critical care. |
|
Biosensors International |
xx% |
Drug-eluting stents & interventional cardiology tools. |
|
Cardiac Science |
xx% |
Automated external defibrillators (AEDs) & stress testing systems. |
Recent Developments
- In May 2024, Siemens launched its Corindus Robotic PCI System, a robot-assisted platform that enhances precision in coronary interventions while reducing procedure time by 25.3%. The system has been widely adopted, with deployments in over 52 hospitals across Europe under Germany’s Disease Management Program.
- In March 2024, Abbott revolutionized cardiac diagnostics by introducing the Troponin-I Ultra Rapid Test, delivering high-sensitivity results in just 8 minutes compared to 20+ minutes for standard assays. It captured 15.1% of the U.S. emergency cardiac testing market within six months, demonstrating rapid clinical adoption.
- Report ID: 7762
- Published Date: Jun 16, 2025
- Report Format: PDF, PPT
Have specific data needs or budget constraints?
Reach out to us for a customized quote or to learn more about our special pricing
for startups and universities
Frequently Asked Questions (FAQ)
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Connect with our Expert
